Author name: Claritas Rx

Payers prefer to back data-based, evidence-driven therapies. Here’s the information they need to understand value.

Rare disease communities and their members offer a valuable source of qualitative data to other patients and healthcare providers.

Prior authorization can be improved by streamlining data collection and communication. Here’s how the Hub helps.

Key opinion leaders (KOLs) drive understanding and knowledge. Here’s how to connect with the top minds in rare diseases.

Data insights in specialty drug distribution drives better decision making. Here’s how the Hub provides key information.

Is your pharmaceutical market access strategy meeting its goals? Here’s what to track.

Complex U.S. payer systems in healthcare don’t lend themselves easily to economic models. Here’s how tech can help.

Which patients are at risk of stopping treatment during treatment and how can you intervene?

Connecting with patient care coordinators helps pharma companies reach rare disease patients with needed treatments.

Do payers understand how distributors add value? Here’s how to communicate the benefits of your distribution strategies.